Status:
WITHDRAWN
Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas
Lead Sponsor:
Patrick Joseph Loehrer Sr.
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine if you can use an assay on tumor samples to see different patterns in response to the same chemotherapy treatment.
Detailed Description
To examine the feasibility of using biodynamic imaging (BDI) as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine...
Eligibility Criteria
Inclusion
- Ability to understand and willingness to sign an informed consent and authorization for release of health information for research
- ≥ 18 years old at time of consent
- Patients with a diagnosis of metastatic pancreatic cancer (mPC) who have not received prior combination chemotherapy. Exception: prior adjuvant chemoradiation with fluorouracil or gemcitabine is allowed.
- Patients considered for routine care treatment with gemcitabine and nab-paclitaxel (allowed to receive other experimental therapy with gem/nab backbone if participating in another clinical trial)
- Measurable disease by RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
- Willingness to undergo transcutaneous core needle biopsy of metastatic tumor for research purposes
- Women are eligible to participate if they are of non-childbearing potential or have documentation of a negative pregnancy test (serum or urine β-hCG) within 1 week of the start of protocol treatment.
- Women and men of childbearing potential must agree to use adequate, highly effective contraceptive measures during protocol treatment
- Laboratory values: Platelets ≥ 100 K/mm3 international normalized ratio (INR) \< 1.2, Partial thromboplastin time (PTT) in normal range, Cr \< 2.0, Total bilirubin \< 2 times upper limit normal (ULN), transaminases \< 5 times ULN
Exclusion
- History of abnormal bleeding with minor procedures or documented platelet aggregation disorder such as VonWillebrand disease
- Women who are pregnant or breastfeeding
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 14 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02205788
Start Date
July 1 2014
End Date
September 14 2016
Last Update
July 10 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.